Locally Advanced or Metastatic Pancreatic Cancer

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AS
AB ScienceFrance - Paris
1 program
1
MasitinibPhase 3Small Molecule1 trial
Active Trials
NCT03766295CompletedEst. Dec 2020
Taiho Oncology
Taiho OncologyNJ - Princeton
1 program
1
S-1Phase 21 trial
Active Trials
NCT00651742Completed28Est. Jul 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AB ScienceMasitinib
Taiho OncologyS-1

Clinical Trials (2)

Total enrollment: 28 patients across 2 trials

Masitinib Plus Gemcitabine in Pancreatic Cancer

Start: Jul 2014Est. completion: Dec 2020
Phase 3Completed

Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer

Start: Jan 2006Est. completion: Jul 200828 patients
Phase 2Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space